Table 3 Factors associated with overall, disease-free, pulmonary progression-free, and systemic treatment free survivals after radiofrequency ablation of lung metastases from renal cell carcinoma (n = 53)
Overall Survival | Pulmonary Progression-free survival | Systemic Treatment-free survival | Disease-free survival | |||||
|---|---|---|---|---|---|---|---|---|
Univariate | Multivariable | Univariate | Multivariable | Univariate | Multivariable | Univariate | Multivariable | |
P (Log-Rank) | HR (95%CI) | P | HR (95%CI) | P | P | P | ||
Sex | ||||||||
Male | 0.94 | – | 0.31 | 0.57 | – | 0.53 | – | |
Female | 2.7 (1.04–7.2) (P = 0.042) | |||||||
Age at RFA | ||||||||
≤ 60 years | 0.67 | – | 0.44 | – | 0.66 | – | 0.94 | – |
< 60 years | ||||||||
Concomitant metastases | ||||||||
Yes | 0.87 | – | 0.85 | – | 0.71 | – | 0.81 | – |
No | ||||||||
Extra-thoracic metastases | ||||||||
Yes | 0.86 | – | 0.73 | – | 0.79 | – | 0.72 | – |
No | ||||||||
T staging | ||||||||
T1-T2 | 0.031 | 1 (Ref.) | 0.024 | 1 (Ref.) | 0.047 | 1 (Ref.) | 0.07 | – |
T3-T4 | 3.55 (1.05–12.1) (P = 0.04) | 3.5 (1.3–9.3) (P = 0.011) | 2.3 (1–5.5) (P = 0.053) | |||||
Fuhrman | ||||||||
1–2 | 0.31 | – | 0.49 | – | 0.26 | – | 0.71 | – |
3–4 | ||||||||
Lung mets size | ||||||||
≤ 20 mm | 1 (Ref.) | 0.73 | – | 0.17 | – | 0.39 | – | |
> 20 mm | 0.019 | 2.56 (0.88–7.5) (P = ns) | ||||||
Number of lung metastases | ||||||||
1 | 0.69 | – | 0.007 | 1 (Ref.) | 0.60 | – | 0.14 | – |
2 | 3.09 (1.1–8.7) (P = 0.032) | |||||||
3 | 3.4 (1.3–9) (P = 0.013) | |||||||